NASDAQ:ALNY

Alnylam Pharmaceuticals - ALNY Stock Forecast, Price & News

$210.76

+8.15 (+4.02%)

(As of 09/28/2022 12:00 AM ET)

Add

Compare

Today's Range: $205.58
▼
$211.50
50-Day Range: $139.95
▼
$233.85
52-Week Range: $117.58
▼
$236.80

Volume: 1.01 million shs
Average Volume: 910,138 shs
Market Capitalization: $25.30 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $232.06

Alnylam Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.71 Rating Score
Upside/Downside: 10.1% Upside
$232.06 Price Target
Short Interest: Bearish
3.65% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.52
Upright™ Environmental Score
News Sentiment: 1.55
Based on 3 Articles This Week
Insider Trading: Selling Shares
$1.03 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($8.13) to ($4.55) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

402nd out of 1,096 stocks

Pharmaceutical Preparations Industry

180th out of 548 stocks

3.4

Analyst's Opinion

Consensus Rating
Alnylam Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 12 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $232.06, Alnylam Pharmaceuticals has a forecasted upside of 10.1% from its current price of $210.76.
Amount of Analyst Coverage
Alnylam Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
3.65% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Alnylam Pharmaceuticals has a short interest ratio ("days to cover") of 4.2.
Change versus previous month
Short interest in Alnylam Pharmaceuticals has recently increased by 4.29%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Alnylam Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Alnylam Pharmaceuticals does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Alnylam Pharmaceuticals has received a 63.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Gene therapy medication", "Clinical research services", and "Preclinical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Alnylam Pharmaceuticals is -1.52.

2.5

News and Social Media Coverage

News Sentiment
Alnylam Pharmaceuticals has a news sentiment score of 1.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Alnylam Pharmaceuticals this week, compared to 4 articles on an average week.
Search Interest
Only 11 people have searched for ALNY on MarketBeat in the last 30 days. This is a decrease of -48% compared to the previous 30 days.
MarketBeat Follows
Only 9 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,033,073.00 in company stock.
Percentage Held by Insiders
Only 1.40% of the stock of Alnylam Pharmaceuticals is held by insiders.
Percentage Held by Institutions
93.21% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($8.13) to ($4.55) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alnylam Pharmaceuticals is -25.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alnylam Pharmaceuticals is -25.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Alnylam Pharmaceuticals has a P/B Ratio of 42.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNY Stock News Headlines

September 21, 2022 | finance.yahoo.com

Alnylam Announces New Management Appointments

September 19, 2022 | finance.yahoo.com

Alnylam to Host Ninth Annual "RNAi Roundtable" Webcast Series

September 18, 2022 | americanbankingnews.com

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Sees Large Drop in Short Interest

September 15, 2022 | nasdaq.com

Investors in Alnylam Pharmaceuticals (NASDAQ:ALNY) have made a impressive return of 144% over the past three years

September 15, 2022 | finance.yahoo.com

Alnylam/Regeneron-Backed NASH Candidate Shows Encouraging Safety Profile In Healthy Volunteers

September 15, 2022 | finance.yahoo.com

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin

September 15, 2022 | finance.yahoo.com

Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers

September 15, 2022 | finance.yahoo.com

Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers

September 13, 2022 | finance.yahoo.com

Regeneron Pharmaceuticals, Inc.: Raising Our Regeneron FVE to $690 After Incorporating High-Dose Eylea and U.S. Drug Pricing Policy

September 12, 2022 | finance.yahoo.com

Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes

September 9, 2022 | nasdaq.com

Alnylam (ALNY) Soars 8.4%: Is Further Upside Left in the Stock?

September 8, 2022 | finance.yahoo.com

Alnylam Shares Detailed Patisiran Data From Rare Disease Study

September 6, 2022 | finance.yahoo.com

Alnylam to Webcast Presentation at Morgan Stanley 20th Annual Global Healthcare Conference

September 4, 2022 | finance.yahoo.com

Want to Beat Alphabet Stock? Buy These 2 Winners of the Bear Market

September 1, 2022 | finance.yahoo.com

Cerveau Technologies Inc. and Alnylam® Pharmaceuticals Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research

August 29, 2022 | nasdaq.com

Alnylam: Additional Data Shows Favorable Effects Of Cemdisiran On Different Measures Of proteinuria

August 29, 2022 | finance.yahoo.com

Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy

August 26, 2022 | finance.yahoo.com

Pfizer 'surprised' by Moderna COVID-19 vaccine patent lawsuit

August 24, 2022 | finance.yahoo.com

Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors

August 18, 2022 | finance.yahoo.com

Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis

August 17, 2022 | msn.com

Will Investors Notice Exciting Sign On Alnylam Pharmaceuticals Chart?

August 12, 2022 | finance.yahoo.com

Is This Unknown Growth Stock a Buy After Its Blast Off?

August 12, 2022 | marketwatch.com

Hemoglobinopathies Market – Business Strategies, Industry Share, Size 2022 to 2030 | By -Gamida Cell, Alnylam Pharmaceuticals, Sanofi

August 8, 2022 | finance.yahoo.com

Karuna’s Schizophrenia-Trial Data Are ‘Best Case Scenario’ for the Biotech Stock

August 5, 2022 | finance.yahoo.com

Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNY Company Calendar

Last Earnings: 7/28/2022
Today: 9/28/2022
Next Earnings (Estimated): 10/27/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:ALNY
CUSIP: 02043Q10
CIK: 1178670
Web: www.alnylam.com
Phone: (617) 551-8200
Fax: 617-551-8101
Employees: 1,665
Year Founded: 2002

Price Target and Rating

Average Stock Price Forecast: $232.06
High Stock Price Forecast: $430.00
Low Stock Price Forecast: $98.00
Forecasted Upside/Downside: +10.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.71
Research Coverage: 17 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($8.17)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-852,820,000.00
Net Margins: -110.91%
Pretax Margin: -110.67%
Return on Equity: -204.18%
Return on Assets: -28.26%

Debt

Debt-to-Equity Ratio: 3.85
Current Ratio: 3.76
Quick Ratio: 3.62

Sales & Book Value

Annual Sales: $844.29 million
Price / Sales: 29.96
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.92 per share
Price / Book: 42.84

Miscellaneous

Outstanding Shares: 120,027,000
Free Float: 118,347,000
Market Cap: $25.30 billion
Optionable: Optionable
Beta: 0.58

Social Links

Key Executives

Mr. Michael W. Bonney B.A. (Age 64)
Exec. Chairman
Comp: $317.97k

Dr. Yvonne L. Greenstreet M.B.A. (Age 59)
MBA, MBChB, CEO & Director
Comp: $1.23M

Dr. Akshay K. Vaishnaw M.D. (Age 59)
Ph.D., Pres
Comp: $1.09M

Mr. Jeffrey V. Poulton M.B.A. (Age 54)
CFO & Exec. VP
Comp: $914.05k

Mr. Tolga Tanguler M.B.A.
Exec. VP & Chief Commercial Officer

Dr. Alfred W. Boyle Ph.D.
Chief Technical Operations & Quality Officer

Dr. Kevin Joseph Fitzgerald Ph.D. (Age 54)
Sr. VP, Head of Research & Chief Scientific Officer

Ms. Christine Regan Lindenboom
Sr. VP of Investor Relations & Corp. Communications

Ms. Indrani M. Lall Franchini J.D. (Age 50)
Exec. VP, Chief Legal Officer & Sec.

Mr. Mark Baglin
VP of Global Marketing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALNY Stock - Frequently Asked Questions

Should I buy or sell Alnylam Pharmaceuticals stock right now?: 17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 5 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALNY shares.
View ALNY analyst ratings or view top-rated stocks.
What is Alnylam Pharmaceuticals' stock price forecast for 2022?: 17 brokers have issued 12 month price targets for Alnylam Pharmaceuticals' stock. Their ALNY share price forecasts range from $98.00 to $430.00. On average, they anticipate the company's share price to reach $232.06 in the next year. This suggests a possible upside of 10.1% from the stock's current price.
View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts.
How have ALNY shares performed in 2022?: Alnylam Pharmaceuticals' stock was trading at $169.58 on January 1st, 2022. Since then, ALNY stock has increased by 24.3% and is now trading at $210.76.
View the best growth stocks for 2022 here.
When is Alnylam Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our ALNY earnings forecast.
How were Alnylam Pharmaceuticals' earnings last quarter?: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) issued its quarterly earnings results on Thursday, July, 28th. The biopharmaceutical company reported ($2.29) EPS for the quarter, missing analysts' consensus estimates of ($1.62) by $0.67. The biopharmaceutical company had revenue of $224.80 million for the quarter, compared to analysts' expectations of $256.06 million. Alnylam Pharmaceuticals had a negative trailing twelve-month return on equity of 204.18% and a negative net margin of 110.91%. The firm's revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period last year, the business posted ($1.61) EPS.
What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings?: Alnylam Pharmaceuticals issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $870.00 million-$930.00 million, compared to the consensus revenue estimate of $1.09 billion.

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?: 65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Alnylam Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).
What is Alnylam Pharmaceuticals' stock symbol?: Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."
Who are Alnylam Pharmaceuticals' major shareholders?: Alnylam Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (11.93%), Baillie Gifford & Co. (8.31%), Price T Rowe Associates Inc. MD (5.83%), Dodge & Cox (4.38%), State Street Corp (2.49%) and Amundi (0.76%). Insiders that own company stock include Akshay Vaishnaw, Barry E Greene, Jeffrey W Dunn, John Maraganore, Laurie Keating, Marsha Fanucci, Phillip A Sharp, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet.
View institutional ownership trends.
How do I buy shares of Alnylam Pharmaceuticals?: Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Alnylam Pharmaceuticals' stock price today?: One share of ALNY stock can currently be purchased for approximately $210.76.
How much money does Alnylam Pharmaceuticals make?: Alnylam Pharmaceuticals (NASDAQ:ALNY) has a market capitalization of $25.30 billion and generates $844.29 million in revenue each year. The biopharmaceutical company earns $-852,820,000.00 in net income (profit) each year or ($8.17) on an earnings per share basis.
How many employees does Alnylam Pharmaceuticals have?: The company employs 1,665 workers across the globe.
How can I contact Alnylam Pharmaceuticals?: Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The official website for the company is www.alnylam.com. The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at investors@alnylam.com, or via fax at 617-551-8101.

This page (NASDAQ:ALNY) was last updated on 9/28/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Alnylam Pharmaceuticals - ALNY Stock Forecast, Price & News

Alnylam Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

ALNY Stock News Headlines

ALNY Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

ALNY Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™